Alto Neuroscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-	-36.31	-27.71	-9.19
Depreciation & Amortization	-	0.65	0.61	0.15
Share-Based Compensation	-	2.89	1.76	0.23
Other Operating Activities	-	-0.69	4.95	-0.45
Operating Cash Flow	-	-33.45	-20.39	-9.26
Capital Expenditures	-	-0.47	-0.73	-0.68
Investing Cash Flow	-	-0.47	-0.73	-0.68
Share Issuance / Repurchase	-	0.18	0.04	0.01
Debt Issued / Paid	-	0	9.67	0
Other Financing Activities	-	67.95	34.07	31.68
Financing Cash Flow	-	68.13	43.79	31.69
Exchange Rate Effect	-	-0.01	-0.02	-0.05
Net Cash Flow	-	34.2	22.64	21.7
Free Cash Flow	-	-33.92	-21.13	-9.94
Free Cash Flow Margin	-	-	-	-4734.29%
Free Cash Flow Per Share	-	-9.09	-6.13	-1.85

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).